Efficacy and safety of CT ‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial

Documenti analoghi

• A long‐acting glucose‐dependent insulinotropic polypeptide receptor agonist improves the gastrointestinal tolerability of glucagon‐like peptide‐1 receptor agonist therapy
  di: Filip K. Knop, et al.
  Pubblicazione: (2024)
• Regulation of glucose and energy metabolism through actions of glucagon‐like peptide‐1 and glucose‐dependent insulinotropic polypeptide
  di: Yasuo Zenimaru, et al.
  Pubblicazione: (2024)
• Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement
  di: Kariem El‐Boghdadly, et al.
  Pubblicazione: (2025)
• Tirzepatide, a dual glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β‐cells and hepatic steatosis in obese type 2 diabetic db/db mice
  di: Yuichiro Iwamoto, et al.
  Pubblicazione: (2024)
• Re: The association between glucose‐dependent insulinotropic polypeptide and/or glucagon‐like peptide‐1 receptor agonist prescriptions and substance‐related outcomes in patients with opioid and alcohol use disorders: A real‐world data analysis
  di: Yanning Wang, et al.
  Pubblicazione: (2025)